Whole-process 3D ECM-encapsulated organoid-based automated high-throughput screening platform accelerates drug discovery for rare diseases

Abstract

Organoid-based high-throughput screening (HTS) is revolutionizing pharmaceutical development. However, the complexity of handling extracellular matrix (ECM) components with traditional HTS devices leads to the use of suspension cultures for organoids during HTS, which alters their transcriptomic landscape and drug responses. Although automated generation techniques for 3D ECM-encapsulated organoids have been established, limitations in operational simplicity and time efficiency remain barriers to achieving high throughput. Here, we develop a whole-process 3D ECM-encapsulated organoid-based automated HTS (wp3D-OAHTS) platform, which achieves superior throughput compared to existing reported systems for 3D organoid drug screening. Utilizing this automated platform, we generated more than 10,000 homogeneous 3D organoid domes of neuroendocrine cervical cancer (NECC) and evaluated their drug responses to 2802 compounds in 13 days. This highly efficient and reproducible approach finally enabled the identification of 5 top hits that significantly inhibited NECC organoids in vitro with half-maximal inhibitory concentration (IC₅₀) of lower than 10 nM. The representative candidate, Quisinostat 2HCl, demonstrated significantly stronger anti-tumor efficacy than clinically used agents in vivo. This platform significantly improves the rapidity and efficiency of 3D ECM-encapsulated organoid drug screening and facilitates new drug discovery for rare diseases.

Keywords

high-throughput screening / organoids / extracellular matrix / neuroendocrine cervical cancer / Quisinostat 2HCl

References

[1] Duan X , Zhang T , Feng L , et al. A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS. Cell Stem Cell 2024; 31: 71- 88.e8.

[2] Luo Z , Wang B , Luo F , et al. Establishment of a large-scale patient-derived high-risk colorectal adenoma organoid biobank for high-throughput and high-content drug screening. BMC Med 2023; 21: 336.

[3] Toshimitsu K , Takano A , Fujii M , et al. Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer. Nat Chem Biol 2022; 18: 605- 14.

[4] Lee SH , Hu W , Matulay JT , et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell 2018; 173: 515- 28.e17.

[5] van de Wetering M , Francies HE , Francis JM , et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015; 161: 933- 45.

[6] Mayoh C , Mao J , Xie J , et al. High-throughput drug screening of primary tumor cells identifies therapeutic strategies for treating children with high-risk cancer. Cancer Res 2023; 83: 2716- 32.

[7] Jarno D , Hans C . Organoids in cancer research. Nat Rev Cancer 2018; 18: 407- 18.

[8] Sato T , Vries RG , Snippert HJ , et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009; 459: 262- 5.

[9] Clevers H . Modeling development and disease with organoids. Cell 2016; 165: 1586- 97.

[10] Xu R , Zhou X , Wang S , et al. Tumor organoid models in precision medicine and investigating cancer-stromal interactions. Pharmacol Ther 2021; 218: 107668.

[11] Huang W , Xu Z , Li S , et al. Living biobanks of organoids:valuable resource for translational research. Biopreserv Biobank 2024; 22: 543- 9.

[12] Driehuis E , Kretzschmar K , Clevers H . Establishment of patient-derived cancer organoids for drug-screening applications. Nat Protoc 2020; 15: 3380- 409.

[13] Kleinman HK , Martin GR . Matrigel:basement membrane matrix with biological activity. Semin Cancer Biol 2005; 15: 378- 86.

[14] Benton G , Arnaoutova I , George J , et al. Matrigel:from discovery and ECM mimicry to assays and models for cancer research. Adv Drug Deliv Rev 2014; 79-80: 3- 18.

[15] Phan N , Hong JJ , Tofig B , et al. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids. Commun Biol 2019; 2: 78.

[16] Tebon PJ , Wang B , Markowitz AL , et al. Drug screening at single-organoid resolution via bioprinting and interferometry. Nat Commun 2023; 14: 3168.

[17] Jiang S , Zhao H , Zhang W , et al. An automated organoid platform with inter-organoid homogeneity and inter-patient heterogeneity. Cell Rep Med 2020; 1: 100161.

[18] Ding S , Hsu C , Wang Z , et al. Patient-derived micro-organospheres enable clinical precision oncology. Cell Stem Cell 2022; 29: 905- 17.e6.

[19] Jun HR , Kang HJ , Ju SH , et al. High-throughput organo-on-pillar (high-TOP) array system for three-dimensional ex vivo drug testing. Biomaterials 2023; 296: 122087.

[20] Jeong M-H , Kim I , Park K , et al. An automated High-Throughput Screening (HTS) spotter for 3D tumor spheroid formation. Int J Mol Sci 2023; 24: 1006.

[21] Lee S-Y , Hwang HJ , Lee DW . Optimization of 3D-aggregated spheroid model (3D-ASM) for selecting high efficacy drugs. Sci Rep 2022; 12: 18937.

[22] Lee DW , Choi SY , Kim SY , et al. A novel 3D pillar/well array platform using patient-derived head and neck tumor to predict the individual radioresponse. Transl Oncol 2022; 24: 101483.

[23] Zhu Y , Sun L , Wu X , et al. Engineered human organoids for biomedical applications. Adv Funct Mater 2024; 34: 2310961.

[24] Zhu Y , Zhang X , Sun L , et al. Engineering human brain assembloids by microfluidics. Adv Mater 2023; 35: e2210083.

[25] Burzawa J , Gonzales N , Frumovitz M . Challenges in the diagnosis and management of cervical neuroendocrine carcinoma. Expert Rev Anticancer Ther 2015; 15: 805- 10.

[26] Gadducci A , Carinelli S , Aletti G . Neuroendrocrine tumors of the uterine cervix:a therapeutic challenge for gynecologic oncologists. Gynecol Oncol 2017; 144: 637- 46.

[27] Tempfer CB , Tischoff I , Dogan A , et al. Neuroendocrine carcinoma of the cervix:a systematic review of the literature. BMC Cancer 2018; 18: 530.

[28] Dayton TL , Alcala N , Moonen L , et al. Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites. Cancer Cell 2023; 41: 2083- 99.e9.

[29] April-Monn SL , Kirchner P , Detjen K , et al. Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies. npj Precis Oncol 2024; 8: 59.

[30] Kawasaki K , Toshimitsu K , Matano M , et al. An organoid biobank of neuroendocrine neoplasms enables genotype-phenotype mapping. Cell 2020; 183: 1420- 35.e21.

[31] Arts J , King P , Mariën A , et al. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res 2009; 15: 6841- 51.

[32] Hoskins PJ , Swenerton KD , Pike JA , et al. Small-cell carcinoma of the cervix:fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol 2003; 21: 3495- 501.

[33] Keeratichamroen S , Lirdprapamongkol K , Svasti J . Mechanism of ECM-induced dormancy and chemoresistance in A549 human lung carcinoma cells. Oncol Rep 2018; 39: 1765- 74.

[34] Brandenberg N , Hoehnel S , Kuttler F , et al. High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays. Nat Biomed Eng 2020; 4: 863- 74.

[35] Bergdorf K , Phifer C , Bharti V , et al. High-throughput drug screening of fine-needle aspiration-derived cancer organoids. STAR Protoc 2020; 1: 100212.

[36] Child F , Ortiz-Romero PL , Alvarez R , et al. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br J Dermatol 2016; 175: 80- 8.

[37] Tjulandin S , Fedyanin M , Vladimirov VI , et al. A multicenter phase II study of the efficacy and safety of quisinostat (an HDAC inhibitor) in combination with paclitaxel and carboplatin chemotherapy (CT) in patients (pts) with recurrent platinum resistant high grade serous epithelial ovarian, primarily peritoneal or fallopian tube carcinoma cancer (OC). J Clin Oncol 2017; 35: 5541- 5541.

RIGHTS & PERMISSIONS

The Author(s). Published by Oxford University Press on behalf of Higher Education Press.